Experimental Therapies for CSR

by Dan Roberts
April 2014
Updated August 18, 2018
Research has shown that corticosteroids produced by the body (endogenous) and administered externally (exogenous) can raise adrenaline levels, which can harm the central retina. Some people have high levels of endogenous steroids that can lead to a condition called central serous retinopathy (CSR), aka central serous chorioretinopathy (CSC). The disease can cause partial or total loss of central (macular) vision in either or both eyes. A typical patient is identified as a middle-aged male with a Type A personality. The condition can be chronic, or it may resolve on its own.
Physicians have tried various drug therapies for CSR, to include tranquilizers, antihistamines, non-steroid anti–inflammatory medications, and beta–blockers, with various levels of success. Surgical interventions have included photodynamic therapy, grid laser photocoagulation, and anti-VEGF injections.
Particular drugs that have been considered for CSR treatment are Interferon alpha 2a, Finasteride, Ketoconazole, and Mifepristone (RU-486). Recent use of Spironolactone and Eplerenone, two prescriptions drugs belonging to a drug category called aldosterone antagonists, has also been yielding some promising results. These treatments are experimental at this time, and should be performed only under a qualified doctor’s care.
For more about CSR, see: